Acadia has released a Practice Video Series, intended for US healthcare professionals, to provide “expert insights” into DayBue for Rett syndrome.
The five-part short video series features Dr. Alan Percy, Pediatric Neurologist at UAB Children’s Rett Clinic CEO, Jane Lane, a research Nurse Manager for the Neurology Division at the same institution and Dr Kathleen Motil, Professor Emeritus of Pediatrics at Baylor College of Medicine and Gastroenterologist at Texas Children’s Hospital.
The video series covers DayBue’s clinical trial results, GI management strategies, and how DayBue plays an important role in comprehensive Rett syndrome care.
https://checkrare.com/watch-the-daybue-trofinetide-in-practice-video-series-to-hear-expert-insights/
As part of their “Direct- to- Consumer” campaign, Acadia is also continuing to hold its “Discovering DayBue Caregiver Series”, which are regular 90 min. online events to educate the Rett community about DayBue. These events feature a clinical presentation by a specialist paediatrician and presentation by a Family Access Manager. The opportunity is also provided for Rett families to ask questions and connect with other caregivers. These online events then remain available on demand.
https://daybue.com/events/
https://daybue.com/past-events/
Social media channels such as youtube, instagram and facebook are also being used as part of Acadia’s omni-channel strategy to spread awareness about DayBue.
https://www.youtube.com/channel/UCNqP32wyKupOe_E6n8RUQ5Q
https://www.instagram.com/daybue_us/
https://www.instagram.com/daybue_us/reel/DFyHndxtlah/
https://www.facebook.com/daybue1/
- Forums
- ASX - By Stock
- NEU
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.69%
!
$14.20

Acadia, page-1311
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $14.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.23 | 3278 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1300 | 14.030 |
1 | 500 | 14.000 |
1 | 357 | 13.970 |
1 | 30 | 13.900 |
1 | 700 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
14.260 | 2920 | 1 |
14.300 | 1000 | 1 |
14.380 | 72 | 1 |
14.400 | 1000 | 1 |
14.460 | 434 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online